-
Mashup Score: 5
Seeing is believing. Patients shown proof of calcification adhered better to statins; those without CAC avoided overtreatment.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis | NEJM - 5 month(s) ago
For patients with asymptomatic severe aortic stenosis and preserved left ventricular ejection fraction, current guidelines recommend routine clinical surveillance every 6 to 12 months. Data from ra…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
https://t.co/XhwVkg86LZ Now we have evidence from a multicentric prospective randomized study, to recommend TAVI in asymptomatic pts w/severe aortic stenosis. Credits to @cpcannon who read and posted this important study on Linkedin. #cardiotwitter #Cardiology #CardioEd
-
-
Mashup Score: 6
There have long been debates regarding the atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases should be addressed pharmacologically. While not all the mechanisms explaining the residual risk are known, TRLs are believed to play a significant role. Gaining a better understanding of the effects of TRL on the atherosclerotic process is crucial for enhancing our knowledge of how to manage hypertriglyceridemia.
Source: us02web.zoom.usCategories: General Medicine News, CardiologistsTweet-
RT @society_eas: Join us for our third LatAm webinar 🌎 and help set a new attendance record: https://t.co/R7m41A2dKG 🟫 Potential atherogeni…
-
-
Mashup Score: 9
Background: There are limited data on the unique cardiovascular disease (CVD), non-CVD, and mortality risks of primary prevention individuals with very high coronary artery calcium (CAC; ≥1000), especially compared with rates observed in secondary prevention populations. Methods: Our study population consisted of 6814 ethnically diverse individuals 45 to 84 years of age who were free of known CVD from MESA (Multi-Ethnic Study of Atherosclerosis), a prospective, observational, community-based cohort. Mean follow-up time was 13.6±4.4 years. Hazard ratios of CAC ≥1000 were compared with both CAC 0 and CAC 400 to 999 for CVD, non-CVD, and mortality outcomes with the use of Cox proportional hazards regression adjusted for age, sex, and traditional risk factors. Using a sex-adjusted logarithmic model, we calculated event rates in MESA as a function of CAC and compared them with those observed in the placebo group of stable secondary prevention patients in the FOURIER clinical trial (Further
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
@VietHeartPA @DBelardoMD @khurramn1 @rcextremebike @DrMarthaGulati @CMichaelGibson @DrMichaelShapir @Drlipid @HeartOTXHeartMD @a_l_bailey @purviparwani @DrOstfeld @drjohnm @RonBlankstein I consider pts w/CAC>1000 a very high risk cohort 👇🏽👇🏽 https://t.co/4umWvFl6v7
-
-
Mashup Score: 7JACC: Cardiovascular Imaging: Just Accepted - 7 month(s) ago
J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.05.015 J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.05.026 J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.06.011 J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.06.013 Roxy Senior and Rajdeep S. Khattar J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.06.014 J Am Coll Cardiol Img. Aug 14, 2024. Epublished DOI: 10.1016/j.jcmg.2024.06.
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet-
And it's open access, congrats to the authors for this admirable endeavour!👇 https://t.co/S1MnXZx08r However, as an usual limitation, it performs better in people with european ancestry (See tweet above) #CardioTwitter #CardioEd #Cardiology #Xtwitter
-
-
Mashup Score: 2
There have long been debates regarding the atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases should be addressed pharmacologically. While not all the mechanisms explaining the residual risk are known, TRLs are believed to play a significant role. Gaining a better understanding of the effects of TRL on the atherosclerotic process is crucial for enhancing our knowledge of how to manage hypertriglyceridemia.
Source: us02web.zoom.usCategories: General Medicine News, CardiologistsTweet-
@society_eas https://t.co/pQsg1Vqtrl
-
-
Mashup Score: 6
There have long been debates regarding the atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases should be addressed pharmacologically. While not all the mechanisms explaining the residual risk are known, TRLs are believed to play a significant role. Gaining a better understanding of the effects of TRL on the atherosclerotic process is crucial for enhancing our knowledge of how to manage hypertriglyceridemia.
Source: us02web.zoom.usCategories: General Medicine News, CardiologistsTweet-
RT @society_eas: Join us for our third LatAm webinar 🌎 and help set a new attendance record: https://t.co/R7m41A2dKG 🟫 Potential atherogeni…
-
-
Mashup Score: 1Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease - 9 month(s) ago
Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients a
Source: www.mdpi.comCategories: General Medicine News, CardiologistsTweet-
@mvaduganathan @CMClase @brendonneuen @ValleAlfonso @MarcoMetra @SantosGallegoMD @kidney_boy @DrMarthaGulati @ErinMichos @AgarwalRajivMD @AndrewJSauer And even less or neutral if associated with SGLT2i https://t.co/Z7eOmy2XC5 https://t.co/0CNpJaYmSG https://t.co/A3qdwyxA8d
-
-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG
-
-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG
-
Very good coverage by @michaelTCTMD and insightful comments by @khurramn1 about the CAUGHT-CAD study. Time is now for a broader use of CAC score in those at intermediate risk for ASCVD! #cardiotwitter #Cardiology #CardioEd https://t.co/3pk7pEY1kt